1. Home
  2. SRPT vs LPLA Comparison

SRPT vs LPLA Comparison

Compare SRPT & LPLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • LPLA
  • Stock Information
  • Founded
  • SRPT 1980
  • LPLA 1989
  • Country
  • SRPT United States
  • LPLA United States
  • Employees
  • SRPT N/A
  • LPLA N/A
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • LPLA Investment Bankers/Brokers/Service
  • Sector
  • SRPT Health Care
  • LPLA Finance
  • Exchange
  • SRPT Nasdaq
  • LPLA Nasdaq
  • Market Cap
  • SRPT N/A
  • LPLA N/A
  • IPO Year
  • SRPT 1997
  • LPLA 2010
  • Fundamental
  • Price
  • SRPT $37.60
  • LPLA $387.16
  • Analyst Decision
  • SRPT Buy
  • LPLA Strong Buy
  • Analyst Count
  • SRPT 23
  • LPLA 13
  • Target Price
  • SRPT $125.43
  • LPLA $369.77
  • AVG Volume (30 Days)
  • SRPT 5.9M
  • LPLA 660.2K
  • Earning Date
  • SRPT 05-06-2025
  • LPLA 05-08-2025
  • Dividend Yield
  • SRPT N/A
  • LPLA 0.31%
  • EPS Growth
  • SRPT N/A
  • LPLA 9.05
  • EPS
  • SRPT N/A
  • LPLA 14.44
  • Revenue
  • SRPT $2,233,371,000.00
  • LPLA $12,896,160,000.00
  • Revenue This Year
  • SRPT $39.01
  • LPLA $25.62
  • Revenue Next Year
  • SRPT $13.35
  • LPLA $11.57
  • P/E Ratio
  • SRPT N/A
  • LPLA $26.82
  • Revenue Growth
  • SRPT 59.15
  • LPLA 25.70
  • 52 Week Low
  • SRPT $34.10
  • LPLA $187.19
  • 52 Week High
  • SRPT $173.25
  • LPLA $390.23
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 33.31
  • LPLA 68.86
  • Support Level
  • SRPT $36.89
  • LPLA $368.12
  • Resistance Level
  • SRPT $39.56
  • LPLA $386.75
  • Average True Range (ATR)
  • SRPT 2.14
  • LPLA 7.61
  • MACD
  • SRPT 0.95
  • LPLA -0.07
  • Stochastic Oscillator
  • SRPT 34.86
  • LPLA 86.11

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: